$402.5 Million

Relay Therapeutics

Follow-on Offering

Bookrunner, October 2021

Relay Therapeutics, Inc. (“Relay” or the “Company”) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay’s Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.